[HTML][HTML] Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory …
C Leng, M Gries, J Ziegler, A Lokshin, P Mascagni… - Experimental …, 2006 - Elsevier
Histone deacetylase (HDAC) inhibitors reduce development of graft-versus-host disease
(GVHD) following allogeneic bone marrow transplantation (BMT). Administration of the
HDAC inhibitor suberonylanilide hydroxamic acid (SAHA) resulted in a significantly reduced
GVHD-dependent mortality following fully major histocompatibility complex–mismatched
allogeneic BMT. However, SAHA treatment did not affect T-cell activation or T-cell expansion
in vitro and in vivo. Therefore, we focused on the effects of SAHA treatment on cytokine …
(GVHD) following allogeneic bone marrow transplantation (BMT). Administration of the
HDAC inhibitor suberonylanilide hydroxamic acid (SAHA) resulted in a significantly reduced
GVHD-dependent mortality following fully major histocompatibility complex–mismatched
allogeneic BMT. However, SAHA treatment did not affect T-cell activation or T-cell expansion
in vitro and in vivo. Therefore, we focused on the effects of SAHA treatment on cytokine …